Comment on: Yohshino et al.: combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Cancer Chemother Pharmacol (2017) 80:1239–1247 von Eichbaum, Michael, Eichbaum, Christine

Volltext

Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors von Edelman, Martin J., Lapidus, Rena, Feliciano, Josephine, Styblo, Miroslav, Beumer, Jan H., Liu, Tao, Gobburu, Jogarao

Volltext

Cytokeratin 8/18 monoclonal antibody was dissimilar to anti-cytokeratin CAM 5.2: Comment on: “A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol. 2010; 65(6): 1009–1021” von Wang, Shao-Chuan, Chen, Fong-Lin, Lin, Wea-Lung, Wang, Po-Hui, Han, Chih-Ping

Volltext

Erratum: Cancer Chemother Pharmacol 45: 133-141

Volltext

Erratum: Cancer Chemother Pharmacol 45:345-349

Volltext

Erratum: Cancer Chemother Pharmacol (1999) 43: 106-114

Volltext

Erratum: Cancer Chemother Pharmacol (1993) 32: 39-45

Volltext

Erratum: Cancer Chemother Pharmacol (1998) 42: 300-306

Volltext

Erratum: Cancer Chemother Pharmacol (1999) 43: 1-7

Volltext

Erratum: Cancer Chemother Pharmacol (1998) 42: 433-440

Volltext

Carboplatin and vinorelbine in advanced non-small-cell lung cancer: Pronzato P, Ghio E, Losardo PL, Landucci M, Vaira F, Vigani A. Oncologia Medica, Ospedale S. Andrea, Loc. Felettino, 1-19100 La Spezia. Cancer Chemother Pharmacol 1996;37:610–612

Volltext

Letter in response to paper by Abratt et al., Cancer Chemother Pharmacol (1992) 30: 495 von Senan, S

Volltext

Antitumor activity of treosulfan in human lung carcinomas: Kopf-Maier P, Sass G. Institut Anatomie, Freie Universitat Berlin, Konigin-Luise-Strasse 15, D-14195 Berlin. Cancer Chemother Pharmacol 1996; 37: 211–221

Volltext

Reduced levels of topoisomerase IIα and IIβ in a multidrug-resistant lung-cancer cell line: Evans CD, Mirski SEL, Danks MK, Cole SPC. Cancer Research Laboratories, Queen's University, Kingston, Ont. K7L 3N6. Cancer Chemother Pharmacol 1994;34:242–248

Volltext

Cyclocreatine in cancer chemotherapy: Teicher BA, Menon K, Northey D, Liu J, Kufe DW. Kaddurah-Daouk Dana-Farber Cancer Institute, Joint Center for Radiation Therapy, 44 Binney Street, Boston, MA 02115. Cancer Chemother Pharmacol 1995;35:411–416

Volltext

Etoposide in the treatment of elderly/poor-prognosis patients with small-cell lung cancer: Carney DN, Byrne A. Mater Misericordiae Hospital, Eccles Street, Dublin 7. Cancer Chemother Pharmacol Suppl. 1994;34:S96–S100

Volltext

Phase I study of ifosfamide plus high-dose epirubicin in advanced non-small-cell lung cancer: Gridelli C, Rossi A, Incoronato P, Bruni GS, Scognamiglio F, Ruffolo P et al. Divisione di Oncologia Medica B, Istituto Nazionale Tumori, Via Semmola, 1-80131 Napoli. Cancer Chemother Pharmacol 1996;37:613–615

Volltext

Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients: Fujiwara Y, Ohune T, Okusaki K, Niitani K, Sumiyoshi H, Takemoto Y et al. H Department of Internal Medicine, Hiroshima Univ. School of Medicine, Kasumi 1-2-3, Minami-ku, Hiroshima 734. Cancer Chemother Pharmacol 1996; 37: 327-31

Volltext

Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer: Soda H, Oka M, Fukuda M, Kinoshita A, Sakamoto A, Araki J et al. Second Department Internal Medicine, Nagasaki University School Medicine, 7-1 Sakamoto I-Chome, Nagaski 852. Cancer Chemother Pharmacol 1996;38:9–12

Volltext

Etoposide-resistant human colon and lung adenocarcinoma cell lines exhitib sensitivity to homoharringtonine : Wilkoff LJ, Dulmadge EA, Vasanthakumar G, Donahue JP. Southern Research Institute, P.O. Box 55305, Birmingham, AL 35255-5305. Cancer Chemother Pharmacol 1993;33:149–53

Volltext